Hanmi – Aptose enter into exclusive WW license agreement

$420 mil deal of HM43239: an oral, highly potent, myeloid kinome inhibitor (MKI) to target leukemia

Hanmi, LegoChem collaborate to develop bispecific ADC cancer drugs

Using Beijing Hanmi’s Pentambody™ to develop a novel cancer treatment

Hanmi, DKU to develop resistant lung cancer-targeted therapy

Research collaboration on innovative new drug targeting resistant lung cancer

Hanmi, GC to co-research/develop rare diseases treatments

Jointly develop a treatment for LSD using patents currently owned by Hanmi

Hanmi to manufacture Genexine’s COVID-19 vaccine

Signed a contract to develop the GX-19N (DNA vaccine) production process and manufacturing

Hanmi promotes clinical use of Keytruda® combi with FLX475

Phase II begins for gastric cancer patients in Korea and China in 1H 2021.

Hanmi and Merck Enter into Licensing Agreement to Develop Efinopegdutide

Once-weekly therapy for Nonalcoholic Steatohepatitis (NASH)

Hanmi Pharm partners with RAPT

Hanmi announces collaboration with RAPT Therapeutics to develop and commercialize FLX475 for cancer treatment

Hanmi Pharm-GC Pharma

Hanmi Pharm & GC Pharma team up to develop rare disease treatment

Hanmi-Standigm

Hanmi Pharm signs an agreement with Standigm to find drug candidates based on AI

Licensing Agreement with Phanes

Hanmi and Phanes announce licensing agreement to develop bi- and/or multi-specific antibodies

“Gugu” to enter Japanese Market

Hanmi’s impotence drug “Gugu” enters Japanese market with “BPH” and Sandoz will take charge of sales.

Co-promotion Agreement with Santen

Hanmi and Santen sign co-promotion accord for dry eye treatments

Hanmi/Beijing Hanmi, Innovent agree to co-
develop bispecific anticancer antibody

Hanmi Pharmaceuticals and Innovent Biologics signed
a global partnership to develop a immuno-oncology bispecific antibody

License agreement with Genentech for a novel
oral RAF inhibitor

Hanmi enters into an exclusive development with Genentech for the development and commercialization
of Hanmi’s pan-RAF inhibitor, HM95573, which is currently in Phase I clinical development

Hanmi-MSD sign contract to export
ROSUZET to 23 countries

Hanmi Pharm responsible for R&D and manufacturing of ROSUZET; MSD responsible for marketing and sales in importing countries

Research collaboration for new anti-cancer drug with Ajou Univ.

Research collaboration to develop novel anti-cancer drug using stem cells covering glioblastoma and various cancer

Licensing agreement for new lung cancer drug with ZAI Lab

Licensing agreement to grant exclusive rights in China (including Hong Kong and Macao) for new lung cancer drug targeting resistance, HM61713, with ZAI Lab, a biotechnology company based in Shanghai, China

Technology transfer of new biologics to Janssen

Licensing agreement for development and commercialization of long-acting GLP-1/Glucagon receptor dual agonist ‘HM12525A’ for the treatment of diabetes and obesity with Janssen, a pharmaceutical company based in New Jersey, USA

Technology transfer of new diabetes program to Sanofi

Licensing agreement for Quantum Project, a long-acting diabetes program, with Sanofi, a pharmaceutical company based in Paris, France

Licensing agreement for immunological therapy with Eli Lilly

Exclusive licensing and collaboration agreement for BTK inhibitor, HM71224, with Eli Lilly, a pharmaceutical company based in Indiana, USA

License out Poziotinib to Spectrum (US)

Worldwide licensing agreement excluding Korea and China, for clinical development, manufacturing, marketing approval and commercialization of Poziotinib with Spectrum baseed in Nevada State, USA

Strategic investment in US R&D venture specialized in ophthalmology

License and co-development rights of Luminate® , novel drug for a retina-related disease, through strategic investment in Allegro Ophthalmics based in California, USA

License out Poziotinib to Luye Pharma (China)

Exclusive licensing agreement for clinical development, manufacturing and approval and sales and marketing after commercialization of Poziotinib in China with Luye Pharma, based in Yantai, China

Co-promotion for diabetes medicines with multinational pharmaceutical company

Co-promotion of anti-diabetic treatment Galvus ® and Galvus MET®, DPP-IV inhibitors, with Novartis, a Swiss multinational pharmaceutical company

Licensing agreement for new drug for neutropenia

Licensing agreement for worldwide license, excluding Korea, China and Japan, for a new medicine for neutropenia with Spectrum based in California, USA

Export of ORASCOVERY technology to Athenex (US)

Licensing agreement with Anthenex, headquatered in NY, for development and commercialization in the US, Europe, etc. of ORASCOVERY technology and a new oral anticancer drug developed using this technology.